From the Journals

Distance from transplant center predicted mortality in chronic liver disease


 

FROM CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

Living more than 150 miles from a liver transplant center was associated with a higher risk of mortality among patients with chronic liver failure, regardless of etiology, transplantation status, or whether patients had decompensated cirrhosis or hepatocellular carcinoma, according to a first-in-kind, population-based study reported in the June issue of Clinical Gastroenterology and Hepatology (doi: 10.1016/j.cgh.2017.02.023).

The findings underscore the need for accessible, specialized liver care irrespective of whether patients with chronic liver failure (CLF) are destined for transplantation, David S. Goldberg, MD, of the University of Pennsylvania, Philadelphia, wrote with his associates. The associations “do not provide cause and effect,” but underscore the need to consider “the broader impact of transplant-related policies that could decrease transplant volumes and threaten closures of smaller liver transplant centers that serve geographically isolated populations in the Southeast and Midwest,” they added.

Dr. David S. Goldberg

Managing chronic liver failure is complex – physicians must treat acute illness, portal hypertension and its complications, and hepatocellular carcinoma. Consequently, several studies have reported that care is best provided by experts at specialized practices, “nearly always” liver transplant centers in large urban areas, the researchers noted. For these reasons, geographic isolation might undermine survival even among the 11 of every 12 CLF patients never undergo transplantation. Because no population-based study had explored this question, the researchers analyzed data from 16,824 patients with CLF who were included in the Healthcare Integrated Research Database between 2006 and 2014.

A total of 879 (5.2%) patients lived more than 150 miles from the nearest liver transplant center, the analysis showed. Even after controlling for etiology of liver disease, this subgroup was at significantly greater risk of mortality (hazard ratio, 1.2; 95% confidence interval, 1.1-1.3; P less than .001) and of dying without undergoing transplantation (HR, 1.2; 95% CI, 1.1-1.3; P = .003) than were patients who were less geographically isolated. Distance from a transplant center also predicted overall and transplant-free mortality when modeled as a continuous variable, with hazard ratios of 1.02 (P = .02) and 1.03 (P = .04), respectively. “Although patients living more than 150 miles from a liver transplant center had fewer outpatient gastroenterologist visits, this covariate did not affect the final models,” the investigators reported. Rural locality did not predict mortality after controlling for distance from a transplant center, and neither did living in a low-income zip code, they added.

Data from the Centers for Disease Control and Prevention indicate that age-adjusted rates of death from liver disease are lowest in New York, where the entire population lives within 150 miles of a liver transplant center, the researchers noted. “By contrast, New Mexico and Wyoming have the highest age-adjusted death rates, and more than 95% of those states’ populations live more than 150 miles from a [transplant] center,” they emphasized. “The management of most patients with CLF is not centered on transplantation, but rather the spectrum of care for decompensated cirrhosis and hepatocellular carcinoma. Thus, maintaining access to specialized liver care is important for patients with CLF.”

Dr. Goldberg received support from the National Institutes of Health. The investigators had no conflicts.

Recommended Reading

EADV: Prophylactic photodynamic therapy benefits transplant recipients
MDedge Hematology and Oncology
Hong Kong zygomycosis deaths pinned to dirty hospital laundry
MDedge Hematology and Oncology
Sirolimus reduced posttransplant skin cancer risk
MDedge Hematology and Oncology
Organ transplant recipients face increased risk of BCC
MDedge Hematology and Oncology
Skin cancer a concern in pediatric solid organ transplant recipients
MDedge Hematology and Oncology
Antiviral medication successful for treating HCV in hepatocellular carcinoma
MDedge Hematology and Oncology
Racial differences in skin cancer risk after organ transplantation
MDedge Hematology and Oncology
Neoadjuvant chemoradiation may give transplant the edge over resection in biliary cancer
MDedge Hematology and Oncology
Hospital infections top WHO’s list of priority pathogens
MDedge Hematology and Oncology
Skin cancer risk similar for liver and kidney transplant recipients
MDedge Hematology and Oncology